Washington University
St Louis, Missouri, 63110, United States
NCT Number: NCT01821781
This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.
This study is active but is not currently recruiting participants.
Up to 21 year
All sexes
Interventional
Phase 2
St Louis, Missouri, 63110, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
Time frame: 1 year post transplant
Time frame: 1 years post transplant
Time frame: within 100 days post transplant
Time frame: 180 days post transplant
Time frame: 2 years post transplant
Time frame: 2 years post transplant
Time frame: 2 years post transplant
Time frame: within 100 days post transplant
Time frame: 2 years post transplant
Time frame: 2 years post transplant
Washington University School of Medicine
Other
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01652092
Albinism, Bare Lymphocyte Syndrome
Minneapolis, Minnesota, United States
View Trial DetailsNCT03513328
Acquired Anemia Hemolytic, Acquired Neutropenia in Newborn
Gainesville, Florida, United States
View Trial DetailsNCT05687474
3-Hydroxy 3-Methyl Glutaric Aciduria, 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency
Liège, Wallonia, Belgium
View Trial DetailsNCT01917708
Albinism, Anemia
Atlanta, Georgia, United States
View Trial Details